Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (336 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-10-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: therapypatientrituximabcountplatelet
  Phrases that lowered it: and safetyreferenceefficacy andscreeningsafety of
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 19.1% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Keywords listed: 28 (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 80.4% (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients NCT00860600 · started 2008 · scored riskier than 67% of active trials completed
• Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients NCT05492409 · started 2022 · scored riskier than 13% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia NCT04687072 · started 2020 · scored riskier than 48% of active trials completed
• Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. NCT01520909 · started 2012 · scored riskier than 88% of active trials completed
• A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP NCT04428255 · started 2020 · scored riskier than 15% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.